Perrigo Plc Revenue Growth Rates (PRGO), Current and Historic Growth - CSIMarket
CSIMarket
 


Perrigo Company Plc  (NYSE: PRGO)
 

PRGO's Revenue Growth by Quarter and Year

Perrigo Plc's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PRGO/growth
https://api.csimarket.com/api/v1/companies/PRGO/fundamentals
https://api.csimarket.com/api/v1/companies/PRGO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
PRGO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 988.60
2nd Quarter June 1,022.80
1st Quarter March 968.50
FY 2,979.90

PRGOs Annual Revenue
Perrigo Plc's Revenue in the fiscal year 2025 $ 4,252.50 millions
Perrigo Plc's Revenue in the fiscal year 2024 $ 4,372.70 millions
Perrigo Plc's Revenue in the fiscal year 2023 $ 4,655.40 millions
Perrigo Plc's Revenue in the fiscal year 2022 $ 4,451.40 millions
Perrigo Plc's Revenue in the fiscal year 2021 $ 4,138.70 millions




PRGO Revenue third quarter 2026 Y/Y Growth Comment
Perrigo Company Plc reported decrease in Revenue in the third quarter 2026 by -5.22% to $ 988.60 millions, from the same quarter in 2025.
The decrease in the third quarter 2026 Perrigo Company Plc's Revenue compares unfavorably to the Company's average Revenue doubling of 9799.96%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 143 other companies have achieved higher Revenue growth. While Perrigo Company Plc' s Revenue decline of -5.22% ranks overall at the positon no. 3032 in the third quarter 2026.




PRGO Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -5.22 %
2nd Quarter June -3.17 %
1st Quarter March -7.17 %
FY   -

Financial Statements
Perrigo Plc's third quarter 2026 Revenue $ 988.60 millions PRGO's Income Statement
Perrigo Plc's third quarter 2025 Revenue $ 1,043.10 millions Quarterly PRGO's Income Statement


PRGO Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -3.34 %
2nd Quarter June 5.61 %
1st Quarter March -12.72 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #144
Healthcare Sector #422
Overall #3032

Revenue Y/Y Growth Statistics
High Average Low
509620.31 % 9799.96 % -99.98 %
(Sep 27 2014)   (Dec 31 2021)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #144
Healthcare Sector #422
Overall #3032
Revenue Y/Y Growth Statistics
High Average Low
509620.31 % 9799.96 % -99.98 %
(Sep 27 2014)   (Dec 31 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Perrigo Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
524352.11 % 9532.68 % -99.98 %
(Dec 28 2013)  


PRGO's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Perrigo Company Plc disclosed fall in Revenue from the second quarter by -3.34% to $ 988.60 millions, from $ 1,022.80 millions achived in the previous reporting period.

But that's not important problem, as Perrigo Plc's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Revenue quarter on quarter growth. While Perrigo Plc's Revenue growth quarter on quarter, overall rank is 1103.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #67
Healthcare Sector #160
Overall #1103
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #67
Healthcare Sector #160
Overall #1103
Revenue Q/Q Growth Statistics
High Average Low
524352.11 % 9532.68 % -99.98 %
(Dec 28 2013)  


PRGO's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Perrigo Company Plc disclosed fall in Revenue from the second quarter by -3.34% to $ 988.60 millions, from $ 1,022.80 millions achived in the previous reporting period.

But that's not important problem, as Perrigo Plc's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Revenue quarter on quarter growth. While Perrigo Plc's Revenue growth quarter on quarter, overall rank is 1103.


Perrigo Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 27 2026)
12 Months Ending (Mar 28 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 27 2025) 12 Months Ending (Jun 28 2025)
Cumulative Revenue 12 Months Ending $ 4,144.00
Y / Y Revenue Growth (TTM) -4.19 %
Year on Year Revenue Growth Overall Ranking # 2826
Seqeuential Revenue Change (TTM) -0.8 %
Seq. Revenue Growth (TTM) Overall Ranking # 2632


Cumulative Revenue growth Comment
Perrigo Plc's cumulative 12 months Revenue continue to decrease, but on the faster rate at -4.19% year on year, at Jun 27 2026 compare to the -3.6% decrease at Mar 28 2026. If the Perrigo Plc's fiscal year would end at Jun 27 2026, annual Revenue would be $4,144 millions.

In the Healthcare sector 401 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2563 to 2826.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 402
Overall # 2826

Revenue TTM Y/Y Growth Statistics
High Average Low
47.24 %
3.77 %
-18.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 379
S&P 500 # 2632
Cumulative Revenue growth Comment
Perrigo Plc's cumulative 12 months Revenue continue to decrease, but on the faster rate at -4.19% year on year, at Jun 27 2026 compare to the -3.6% decrease at Mar 28 2026. If the Perrigo Plc's fiscal year would end at Jun 27 2026, annual Revenue would be $4,144 millions.

In the Healthcare sector 401 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2563 to 2826.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 402
Overall # 2826

Revenue TTM Y/Y Growth Statistics
High Average Low
47.24 %
3.77 %
-18.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 379
S&P 500 # 2632




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PRGO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Sep 26 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 26 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Milestone Scientific Inc -5.95%$ -5.948 millions


About Perrigo Plc Revenue Growth Rates (PRGO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Perrigo Co Plc (CIK 1585364).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001585364-26-000162
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Perrigo Co Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.